Zentalis Other Stockholder Equity vs Accounts Payable Analysis

ZNTL Stock

USD 3.48 0.02 0.57%

Zentalis Pharmaceuticals financial indicator trend analysis is more than just analyzing Zentalis Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zentalis Pharmaceuticals is a good investment. Please check the relationship between Zentalis Pharmaceuticals Other Stockholder Equity and its Accounts Payable accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Other Stockholder Equity vs Accounts Payable

Other Stockholder Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zentalis Pharmaceuticals Other Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have totally related.

The correlation between Zentalis Pharmaceuticals' Other Stockholder Equity and Accounts Payable is 0.99. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Zentalis Pharmaceuticals Llc, assuming nothing else is changed. The correlation between historical values of Zentalis Pharmaceuticals' Other Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Zentalis Pharmaceuticals Llc are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Stockholder Equity i.e., Zentalis Pharmaceuticals' Other Stockholder Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Other Stockholder Equity

Accounts Payable

An accounting item on the balance sheet that represents Zentalis Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Zentalis Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Zentalis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zentalis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Tax Provision is expected to rise to about (784.7 K) this year. The value of Selling General Administrative is expected to slide to about 37.1 M

	2010	2019	2023	2024 (projected)
Interest Income	355K	498K	572.7K	469.2K
Net Interest Income	355K	498K	572.7K	469.2K

Interest Income Net Interest Income

Zentalis Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.97	0.98	1.0	0.11	0.96	0.91	0.51	-0.88	0.98	0.4	0.86	0.43	0.91	1.0	0.79	-0.47	-0.88	0.96	0.91	0.89	0.98	0.97	1.0	0.75	1.0
Other Current Liab	0.97		1.0	0.96	0.23	0.93	0.91	0.58	-0.93	0.98	0.31	0.82	0.48	0.93	0.97	0.87	-0.52	-0.82	0.97	0.93	0.88	1.0	0.98	0.96	0.74	0.97
Total Current Liabilities	0.98	1.0		0.97	0.19	0.94	0.92	0.57	-0.92	0.99	0.34	0.83	0.5	0.93	0.98	0.86	-0.52	-0.84	0.97	0.94	0.86	1.0	0.99	0.97	0.77	0.98
Total Stockholder Equity	1.0	0.96	0.97		0.1	0.96	0.89	0.47	-0.87	0.98	0.42	0.84	0.42	0.9	1.0	0.77	-0.46	-0.88	0.95	0.89	0.89	0.97	0.95	1.0	0.74	1.0
Other Liab	0.11	0.23	0.19	0.1		-0.03	0.02	-0.34	-0.13	0.07	0.42	-0.07	-0.08	-0.01	0.13	0.13	0.05	-0.33	0.31	0.06	0.28	0.2	0.13	0.14	-0.25	0.13
Net Tangible Assets	0.96	0.93	0.94	0.96	-0.03		0.86	0.64	-0.94	0.96	0.27	0.81	0.58	0.97	0.96	0.87	-0.66	-0.82	0.91	0.87	0.84	0.94	0.92	0.95	0.81	0.96
Property Plant And Equipment Net	0.91	0.91	0.92	0.89	0.02	0.86		0.61	-0.82	0.91	0.33	0.98	0.32	0.89	0.87	0.78	-0.39	-0.74	0.84	1.0	0.81	0.9	0.97	0.89	0.81	0.88
Net Debt	0.51	0.58	0.57	0.47	-0.34	0.64	0.61		-0.71	0.56	-0.49	0.53	0.48	0.76	0.48	0.81	-0.61	-0.12	0.42	0.64	0.49	0.56	0.61	0.44	0.59	0.49
Retained Earnings	-0.88	-0.93	-0.92	-0.87	-0.13	-0.94	-0.82	-0.71		-0.91	-0.18	-0.72	-0.71	-0.98	-0.88	-0.97	0.8	0.75	-0.91	-0.85	-0.77	-0.92	-0.9	-0.86	-0.81	-0.88
Accounts Payable	0.98	0.98	0.99	0.98	0.07	0.96	0.91	0.56	-0.91		0.34	0.84	0.54	0.93	0.98	0.82	-0.53	-0.85	0.96	0.92	0.81	0.99	0.97	0.98	0.82	0.98
Cash	0.4	0.31	0.34	0.42	0.42	0.27	0.33	-0.49	-0.18	0.34		0.39	0.03	0.16	0.39	0.02	0.0	-0.76	0.48	0.28	0.29	0.32	0.32	0.47	0.28	0.39
Non Current Assets Total	0.86	0.82	0.83	0.84	-0.07	0.81	0.98	0.53	-0.72	0.84	0.39		0.21	0.82	0.81	0.68	-0.3	-0.72	0.75	0.95	0.76	0.81	0.9	0.84	0.78	0.81
Non Currrent Assets Other	0.43	0.48	0.5	0.42	-0.08	0.58	0.32	0.48	-0.71	0.54	0.03	0.21		0.62	0.45	0.63	-0.9	-0.43	0.55	0.35	0.13	0.5	0.44	0.42	0.74	0.45
Other Assets	0.91	0.93	0.93	0.9	-0.01	0.97	0.89	0.76	-0.98	0.93	0.16	0.82	0.62		0.9	0.96	-0.73	-0.74	0.88	0.91	0.81	0.93	0.93	0.89	0.84	0.9
Cash And Short Term Investments	1.0	0.97	0.98	1.0	0.13	0.96	0.87	0.48	-0.88	0.98	0.39	0.81	0.45	0.9		0.79	-0.48	-0.88	0.97	0.88	0.89	0.98	0.95	0.99	0.73	1.0
Net Receivables	0.79	0.87	0.86	0.77	0.13	0.87	0.78	0.81	-0.97	0.82	0.02	0.68	0.63	0.96	0.79		-0.79	-0.61	0.81	0.82	0.77	0.85	0.85	0.76	0.72	0.79
Good Will	-0.47	-0.52	-0.52	-0.46	0.05	-0.66	-0.39	-0.61	0.8	-0.53	0.0	-0.3	-0.9	-0.73	-0.48	-0.79		0.45	-0.55	-0.42	-0.33	-0.52	-0.48	-0.45	-0.69	-0.48
Common Stock Total Equity	-0.88	-0.82	-0.84	-0.88	-0.33	-0.82	-0.74	-0.12	0.75	-0.85	-0.76	-0.72	-0.43	-0.74	-0.88	-0.61	0.45		-0.92	-0.73	-0.74	-0.84	-0.8	-0.91	-0.68	-0.88
Common Stock Shares Outstanding	0.96	0.97	0.97	0.95	0.31	0.91	0.84	0.42	-0.91	0.96	0.48	0.75	0.55	0.88	0.97	0.81	-0.55	-0.92		0.86	0.83	0.98	0.94	0.96	0.74	0.97
Non Current Liabilities Total	0.91	0.93	0.94	0.89	0.06	0.87	1.0	0.64	-0.85	0.92	0.28	0.95	0.35	0.91	0.88	0.82	-0.42	-0.73	0.86		0.82	0.92	0.98	0.89	0.8	0.88
Other Current Assets	0.89	0.88	0.86	0.89	0.28	0.84	0.81	0.49	-0.77	0.81	0.29	0.76	0.13	0.81	0.89	0.77	-0.33	-0.74	0.83	0.82		0.87	0.86	0.88	0.44	0.89
Other Stockholder Equity	0.98	1.0	1.0	0.97	0.2	0.94	0.9	0.56	-0.92	0.99	0.32	0.81	0.5	0.93	0.98	0.85	-0.52	-0.84	0.98	0.92	0.87		0.98	0.97	0.75	0.98
Total Liab	0.97	0.98	0.99	0.95	0.13	0.92	0.97	0.61	-0.9	0.97	0.32	0.9	0.44	0.93	0.95	0.85	-0.48	-0.8	0.94	0.98	0.86	0.98		0.95	0.8	0.95
Net Invested Capital	1.0	0.96	0.97	1.0	0.14	0.95	0.89	0.44	-0.86	0.98	0.47	0.84	0.42	0.89	0.99	0.76	-0.45	-0.91	0.96	0.89	0.88	0.97	0.95		0.74	0.99
Property Plant And Equipment Gross	0.75	0.74	0.77	0.74	-0.25	0.81	0.81	0.59	-0.81	0.82	0.28	0.78	0.74	0.84	0.73	0.72	-0.69	-0.68	0.74	0.8	0.44	0.75	0.8	0.74		0.73
Total Current Assets	1.0	0.97	0.98	1.0	0.13	0.96	0.88	0.49	-0.88	0.98	0.39	0.81	0.45	0.9	1.0	0.79	-0.48	-0.88	0.97	0.88	0.89	0.98	0.95	0.99	0.73

Click cells to compare fundamentals

Zentalis Pharmaceuticals Account Relationship Matchups

Zentalis Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	102.7M	365.6M	454.5M	539.3M	551.7M	376.7M
Other Current Liab	9.8M	18.6M	29.9M	45.4M	54.2M	29.5M
Total Current Liabilities	14.9M	28.6M	43.9M	56.6M	69.4M	40.3M
Total Stockholder Equity	76.8M	333.4M	364.5M	434.0M	437.3M	306.3M
Other Liab	4.2M	2.5M	1.6M	3.5M	3.1M	2.3M
Net Tangible Assets	(92.6M)	296.0M	360.2M	433.8M	498.9M	523.8M
Property Plant And Equipment Net	2.8M	3.6M	52.8M	50.1M	41.7M	27.8M
Net Debt	(81.6M)	(53.0M)	(13.8M)	2.1M	15.1M	15.9M
Retained Earnings	(83.0M)	(200.8M)	(359.6M)	(596.4M)	(888.6M)	(844.1M)
Accounts Payable	4.3M	8.7M	11.6M	11.2M	14.9M	9.9M
Cash	82.4M	55.0M	59.7M	43.1M	28.0M	39.1M
Non Current Assets Total	18.6M	20.5M	103.7M	87.4M	55.0M	54.9M
Non Currrent Assets Other	2.2M	2.3M	2.6M	(1.8M)	9.5M	10.0M
Other Assets	0.0	4.3M	9.7M	12.4M	14.2M	14.9M
Cash And Short Term Investments	82.4M	338.5M	339.9M	437.4M	482.9M	312.8M
Net Receivables	140K	417K	2.6M	7.0M	8.1M	8.5M
Common Stock Total Equity	25K	41K	45K	59K	53.1K	50.4K
Common Stock Shares Outstanding	35.9M	41.0M	42.7M	52.9M	65.4M	46.9M
Liabilities And Stockholders Equity	102.7M	365.6M	454.5M	539.3M	551.7M	376.7M
Non Current Liabilities Total	4.2M	3.6M	46.1M	48.6M	44.9M	27.5M
Capital Lease Obligations	781K	2.0M	45.9M	45.2M	43.2M	25.1M
Other Current Assets	1.5M	11.2M	8.0M	29.1M	13.8M	11.8M
Other Stockholder Equity	159.7M	509.3M	723.6M	1.0B	1.3B	687.1M
Total Liab	19.1M	32.2M	90.0M	105.3M	114.3M	67.7M
Net Invested Capital	76.8M	308.6M	364.0M	433.8M	437.3M	290.6M
Property Plant And Equipment Gross	2.8M	3.6M	53.6M	7.7M	44.9M	47.1M
Total Current Assets	84.1M	345.1M	350.8M	451.9M	496.7M	321.8M
Accumulated Other Comprehensive Income	(141.7M)	36K	(125K)	(1.4M)	2.2M	2.3M
Capital Stock	25K	41K	45K	59K	70K	66.5K
Net Working Capital	69.2M	316.5M	306.8M	395.3M	427.4M	281.5M
Common Stock	25K	41K	45K	59K	70K	66.5K
Property Plant Equipment	2.8M	3.6M	8.1M	7.7M	8.9M	5.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:

How To Invest In Zentalis

Details

Is Zentalis Stock a good investment?

Details

What is Zentalis Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.50)

Revenue Per Share

0.572

Return On Assets

(0.25)

Return On Equity

(0.43)

The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zentalis Other Stockholder Equity vs Accounts Payable Analysis

Other Stockholder Equity vs Accounts Payable

Other Stockholder Equity vs Accounts Payable Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Accounts Payable

Zentalis Pharmaceuticals fundamental ratios Correlations

Zentalis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zentalis Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Other Stockholder Equity	+ 1.0	Other Current Liab

Other Assets	- 0.98	Retained Earnings
Net Receivables	- 0.97	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Retained Earnings	- 0.93	Other Current Liab
Common Stock Shares Outstanding	- 0.92	Common Stock Total Equity
Other Stockholder Equity	- 0.92	Retained Earnings